Pregnant women could soon have subsidised access to the bivalent respiratory syncytial virus vaccine Abrysvo, just two months after it was approved by the TGA.

The PBAC has recommended listing the vaccine on the National Immunisation Program (NIP) to prevent lower respiratory tract illness in infants from birth until six months of age via maternal immunisation.

The recombinant respiratory syncytial virus (RSV) pre-fusion F protein vaccine is indicated for active immunisation of pregnant women at 24-36 weeks’ gestation, and adults aged 60 and over.

Sponsor Pfizer Australia’s first attempt at a NIP listing was knocked back in March after the committee found it would not be cost-effective.